ICDs (implantable cardioverter defibrillators) give Medtronic earnings boost at start of FY2005
This article was originally published in Clinica
Executive Summary
Boasting 31% growth in sales for the first quarter, Medtronic's implantable cardioverter defibrillator (ICD) business got off to an auspicious start for fiscal 2005. Despite shortfalls in the company's other businesses, the star performance by its ICD franchise pulled the group's quarterly net earnings up to $529.7m - an 18% increase from the first quarter last year - and enabled the company to meet analysts' estimates.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.